ArticleFrontiers in pediatrics2026
Sublingual methylcobalamin treatment in infants with prolonged jaundice due to vitamin B12 deficiency.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Ineffective erythropoiesis resulting from vitamin B12 deficiency leads to hemolysis. The breakdown of erythrocytes increases plasma bilirubin levels, which can cause jaundice in newborns. Methods: This descriptive cross-sectional study was conducted at the Department of Pediatric Hematology, Antalya Training and Research Hospital. In total, 103 infants with prolonged neonatal jaundice due to vitamin B12 deficiency, defined as a serum level below 250 ng/L, were included. Participants were divided into two groups based on treatment type: sublingual methylcobalamin (Group 1, Results: The mean gestational ages were 38.36 ± 1.4 weeks in Group 1 and 38.87 ± 0.81 weeks in Group 2. The mean ages at diagnosis were 35.74 ± 13.17 days and 35.9 ± 11.73 days, respectively. The female-to-male ratios were 30:42 in Group 1 and 16:15 in Group 2. Mean serum vitamin B12 levels in Group 1 were 138.82 ± 50.09 ng/L before treatment, 656.86 ± 333.16 ng/L at 1.5 months, and 394.08 ± 169.94 ng/L at 3 months following sublingual methylcobalamin therapy. In Group 2, the mean levels were 165.71 ± 56.07 ng/L before treatment, 502.9 ± 196.07 ng/L at 1.5 months, and 345.77 ± 115.42 ng/L at 3 months after intramuscular cyanocobalamin administration. Conclusion: Vitamin B12 deficiency may be associated with prolonged jaundice in neonates. Early diagnosis of vitamin B12 deficiency enables timely initiation of sublingual methylcobalamin, a non-invasive and effective treatment option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.